(NASDAQ:MNMD – Free Report) by 9.9% in the third quarter, according to its most recent 13F filing with the Securities and ...

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead ...

Omeros Corporation's (OMER) stock surged 55% after positive trial results for narsoplimab, a potential treatment for stem ...

Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...

MindMed Inc. has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically ...